PJBioPharmaSolutions.com 

PJ BioPharma Solutions Satisfied Clients (2)
Isomorphic Labs and DeepMind (subsidiaries of Google/Alphabet
(https://www.isomorphiclabs.com/) & (https://deepmind.com/)
Paul provided consulting services to DeepMind on the Isomorohic Labs business formation, strategy and partnering decisions. He was also instrumental in selecting the new BD lead for the business. 
DeepMind, and subsequently Isomorphic Labs, are world leading AI companies owned by Alphabet/Google.
Using remarkable breakthrough AI capability, DeepMind is able to determine complex 3D protein structures when simply provided with a protein's amino acid sequence. They have now made over 200 million protein structures available for public use.
Isomorphic Labs is now using this AI technology and deep learning to transform the new drug discovery process and design new medicines using computer modeling, even before entering the laboratory. 
The DeepMind and Isomorphic Labs capabilities could totally revolutionize new drug discovery and as a result Isomorphic Labs announced collaborative deals with Lilly and Novartis at JPM 2024. These deals are valued at $3B 
Paul carefully listens to the client needs and designs a unique analytical, strategic or partnering plan, adding others to the consulting team as needed, to provide a customized complete business solution. 

He is proud of the projects completed for the highly satisfied clients below.
Diapin Therapeutics (https://www.diapin.com/)
Paul is providing business strategy & advisory services to Diapin, a company developing new products for CV and metabolic diseases. Their lead compounds include DT-109 for MASH, which just completed non-human primate studies showing remarkable results
(https://www.biospace.com/article/diapin-therapeutics-website-announces-publication-of-groundbreaking-results-from-the-latest-study-their-compound-dt-109-a-novel-oral-tripeptide-that-inhibits-nash-progression-in-non-human-primates/) and DT-678.
DT-678 is a novel analog of clopidogrel. The DT-678 differential advantage is that it does not require the complex liver metabolism necessary to release the active metabolite. Instead the molecule is rapidly metabolized in the bloodstream and yields consistent levels of active metabolite regardless of the patient's CYPC-219 genetic status.
DT-678 is presently in full clinical development in China and is available for investment or partnering to enable the start of clinical trials in the US.
Ricovr Healthcare (https://www.ricovr.net/)
Paul is providing business strategy & advisory services to Ricovr Healthcare.
Ricovr owns breakthrough technology, XALIVA, to provide the first truly portable saliva-based rapid-results testing device. While this technology can be applied to many conditions and diseases, the first product launch will be a rapid point of care THC detection diagnostic.
Ricovr's product, anticipated to launch in 2024, will provide employers, law enforcement, and healthcare systems faster, actionable data with regard to recent THC use.